Speakers

4th Industrial Revolution and Biopharmaceuticals

Se Chang Kwon
Se Chang, Kwon
Hanmi Pharm.
Nov. 30 14:20~15:00

Abstract

Of the new industries of the Fourth Industrial Revolution including artificial intelligence(AI), robot, virtual reality (VR), internet of things (IoT), bio, three-dimension (3D) and printing, scientists expects bio-industry, which is closely related to productivity, health and welfare of human will lead the Fourth Industrial Revolution. However, despite its importance, the level of technology or research environment is far insufficient in comparison to other developed countries. As the global industrial structure is rapidly reorganized into variety of industries, it is necessary for Korea to focus on new growth engines.

Using biotechnology (BT) such as DNA, protein and cell, bioindustry creates varieties of value-added products and services, including biopharmaceuticals, bio-food, biochemistry, bio-environment, bioelectronics, bioprocess and devices, bioenergy and resources, bio-verification and information services. In the published OECD (2009) report, rapidly developing biotechnology is expected to open the new era of bioeconomy, and by 2030, its socio-economic impact will be significantly enlarged.

According to Korea Health Industry Development Institutes (KHIDI), global biopharmaceutical market size of 2013 was worth 162.6M USD. By 2020 it is expected to grow up to 278.0M USD. Biopharmaceutical is about 25% of the total pharmaceutical market, and is expected to grow 7.6% annually. Red bioindustry, fusion-bio & smart health care industry which takes up approximately 70% of bioindustry is presumed to grow much rapidly, and biopharmaceuticals such as antibody drugs account for approximately 30% of total pharmaceutical market, growing at a CAGR of 5% during 2013 – 2020. Moreover, post-treatment-focused medical activities will shift to preventive care through gene expression analysis, and gene expression analysis market is expected to grow rapidly from 2.4B USD in 2014 to 8.7B USD in 2020 (EvaluatePharma 2015). With the advent of combining biotechnology with different fields, various new industrial opportunity can be anticipated with the application of biotechnology to other fields of industry.

As individual organizations cannot take on all roles in the field of healthcare, mutual cooperation is crucial in the Fourth Industrial Revolution. To this end, Open Innovation between universities and corporations is emphasized, and through this, efforts are made to create synergies through combination of internal / external technologies and to accelerate innovation and expand market through external sources.

 

Biography

  • 2017.03-Now, Hanmi President/CEO
  • 2012-2017.02, Hanmi Executive Vice President Managing Research Director
  • 2010-2011, Hanmi Research Center Deputy Managing Director
  • 1996-2009, Hanmi Research Center Research Director
  • 1989-1996, SK Chemicals/Biotechnology Team Principal Scientist

 

Education

  • 2009, Seoul National University, College of Agricultural Biotechnology, Biotechnology Ph.D.
  • 1988, Yonsei University, Graduate School of Biochemistry, Biochemistry M.S.
  • 1986, Yonsei University, Department of Biochemistry, Biochemistry B.S.

 

Professional Career

  • 2017.03-Now, Korea Biotech R&D Group Examiner
  • 2016-Now, Ministry of Science and ICT Bio Select Committee Member of Select Committee
  • 2013-Now, Korea Pharmaceutical Manufacturers Association, Council for the Development of Drugs Assistant Administrator
  • 2012-Now, Korean Society of Applied Pharmacology Deputy Director
  • 2013-2014, National Science & Technology Strategy Roadmap Member of Executive Committee

 

Awards and Honors

  • 2016, Hong Jinki Creator Award The Yumin Cultural Foundation
  • 2011, Korea Industrial Technology Promotion Award Ministry of Knowledge Economy
  • 2010, Best Technology Award Ministry of Knowledge Economy